Rexahn and TheraTarget Form Nano Science Research Collaboration
News Dec 15, 2009
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, and TheraTarget, Inc., a developer of polymer therapeutics for the treatment of cancer, have announced the formation of a joint research collaboration agreement.
Under the terms of the agreement, TheraTarget will synthesize and supply Rexahn with polymer-drug conjugate products, which are part of Rexahn’s polymer-based nanomedicine portfolio.
“Through this collaboration with TheraTarget, we hope to strategically expand our targeted drug delivery product line,” said Dr. Chang Ahn, Rexahn’s Chairman and Chief Executive Officer. “We believe that combining TheraTarget’s nanotechnology target drug delivery with Rexahn’s existing portfolio of potent anti-cancer compounds and strong oncology discovery platform may help us develop more effective and less disruptive cancer treatments for patients.”
The class of compounds to be synthesized use technology pioneered by Dr. Jindrich (Henry) Kopecek, co-founder of TheraTarget. The compounds are composed of chains of polymers, to which anti-cancer drugs are attached. The compounds are able to target cancerous cells, and deliver the cell-killing agents. Because of their high molecular weight, the compounds stay active in the bloodstream longer than conventional pharmaceuticals, thereby enhancing dose efficacy.
“We believe that these compounds may offer a better treatment option to patients because of their specific tumor delivery properties, potentially providing us with more precision and the ability to target cancer-fighting drugs to cancer cells,” said Dr. Hamid Ghandehari, co-founder of TheraTarget.
“In addition, because the active agents for these product candidates have been used to fight cancer for decades, they are well-characterized which should be helpful as we look ahead to the FDA review process.”
The agreement includes the exchange of scientific and technological information and technological research materials. Specific collaborative projects now under consideration include the synthesis and characterization of a series of anticancer drug conjugates with and without targeting ligands of selected HPMA (N-(2-hydroxypropyl)methacrylamide) copolymer-drug conjugates, and the optimization of HPMA copolymer-drug conjugates.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.
Ancient Syphilis Genomes Decoded for First TimeNews
Researchers recovered three genomes of the bacterium Treponema pallidum from skeletal remains from colonial-era Mexico, and were able to distinguish the subspecies that causes syphilis from the subspecies that causes yaws. It was not previously thought possible to recover DNA from this bacterium from ancient samples.